Get the Stockscreener App
54.51
0.35%
-0.19
Structure Therapeutics Inc Adr stock is traded at $54.51, with a volume of 555.83K.
It is down -0.35% in the last 24 hours and up +7.75% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$54.70
Open:
$54.61
24h Volume:
555.83K
Relative Volume:
0.80
Market Cap:
$3.87B
Revenue:
-
Net Income/Loss:
$-170.73M
P/E Ratio:
-20.25
EPS:
-2.6921
Net Cash Flow:
$-159.70M
1W Performance:
+2.58%
1M Performance:
+7.75%
6M Performance:
-22.21%
1Y Performance:
+194.17%
1-Day Range:
$52.81
$54.99
1-Week Range:
$51.00
$55.00
52-Week Range:
$18.26
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
54.51 | 3.83B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - TradingView
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? - TradingView
Structure Therapeutics Slumps As Analysts Turn Sharply Bearish - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
HC Wainwright Has Bearish Forecast for GPCR Q3 Earnings - MarketBeat
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Renaissance Technologies LLC Sells 59,400 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - MarketBeat
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
GPCR SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Citizens lowers Structure Therapeutics stock price target on GLP agonist By Investing.com - Investing.com South Africa
Citigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00 - MarketBeat
Structure Therapeutics (GPCR) awards options and RSUs to its CCO - Stock Titan
Structure Therapeutics Inc. (GPCR) files initial Form 3 for CCO - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Given New $110.00 Price Target at Citizens Jmp - MarketBeat
Citizens lowers Structure Therapeutics stock price target on GLP agonist - Investing.com
Structure Therapeutics Chief Commercial Officer John Joseph Berrios files initial beneficial ownership statement - Bitget
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Buy Rating Reiterated on Structure Therapeutics as Obesity Pipeline Advances; $104 Price Target Maintained - TipRanks
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
FMR LLC discloses major 13.2% GPCR stake in Structure Therapeutics Inc (GPCR) - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT) - The Globe and Mail
Structure Therapeutics (GPCR) CSO sells 3,939 ADS after option exercise - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK) - The Globe and Mail
Structure Therapeutics Inc. (GPCR) Stock Analysis: Potential Upside of 116.78% Amid Promising Clinical Trials - DirectorsTalk Interviews
Avidity Partners Management LP Buys Shares of 30,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded at Wall Street Zen - MarketBeat
Janus Henderson Group PLC Purchases 264,833 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (GPCR) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Rock Springs Capital Management LP Sells 108,019 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Orbimed Advisors LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC) - The Globe and Mail
GPCR|Structure Therapeutics Inc|Price:49.000| - TradingKey
Form 4 Structure Therapeutics Inc ADR For: 24 July By Investing.com - Investing.com South Africa
A small-cap contender looking to challenge the weight-loss drug giants | 2026-07-24 | Investing News - Stockhouse
FMR LLC Discloses Major Beneficial Ownership Changes in Structure Therapeutics Inc. - Kalkine Media
FMR LLC funds sell 17,452 Structure Therapeutics (GPCR) ADS at $50.07 - Stock Titan
PSquared Asset Management AG Buys Shares of 35,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
GPCR: Structure Therapeutics IncADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - TradingView
Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Monashee Investment Management LLC - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
SEB Asset Management AB Purchases New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Does EU Approval of Wegovy Pill Change NVO's Competitive Story? - TradingView
(GPCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week - TechStock²
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):